125 related articles for article (PubMed ID: 1525595)
1. Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin.
Goulding A; Gold E; Feng W
Bone Miner; 1992 Aug; 18(2):143-52. PubMed ID: 1525595
[TBL] [Abstract][Full Text] [Related]
2. Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat.
Goulding A; Fisher L
J Bone Miner Res; 1991 Nov; 6(11):1177-81. PubMed ID: 1805541
[TBL] [Abstract][Full Text] [Related]
3. 17 beta-estradiol protects rats from osteopenia associated with administration of the luteinising hormone releasing hormone (LHRH) agonist, buserelin.
Goulding A; Fisher L
Bone Miner; 1991 Apr; 13(1):47-53. PubMed ID: 1905969
[TBL] [Abstract][Full Text] [Related]
4. Norethindrone acetate only partially protects the skeleton of rats treated with the LHRH agonist buserelin from oestrogen-deficiency osteopaenia.
Goulding A; Gold E
J Endocrinol; 1993 Apr; 137(1):27-33. PubMed ID: 8492074
[TBL] [Abstract][Full Text] [Related]
5. Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat.
Goulding A; Gold E
Calcif Tissue Int; 1990 Jan; 46(1):14-9. PubMed ID: 2104770
[TBL] [Abstract][Full Text] [Related]
6. A new way to induce oestrogen-deficiency osteopaenia in the rat: comparison of the effects of surgical ovariectomy and administration of the LHRH agonist buserelin on bone resorption and composition.
Goulding A; Gold E
J Endocrinol; 1989 May; 121(2):293-8. PubMed ID: 2502594
[TBL] [Abstract][Full Text] [Related]
7. Flutamide-mediated androgen blockade evokes osteopenia in the female rat.
Goulding A; Gold E
J Bone Miner Res; 1993 Jun; 8(6):763-9. PubMed ID: 8328318
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen and norethisterone: effects on plasma cholesterol and total body calcium content in the estrogen-deficient rat.
Gold E; Stapley S; Goulding A
Horm Metab Res; 1994 Feb; 26(2):100-3. PubMed ID: 8200611
[TBL] [Abstract][Full Text] [Related]
9. In the ovariectomized rat, tamoxifen conserves bone similarly in parathyroid-intact and parathyroidectomized animals.
Goulding A; Gold E
Bone; 1994; 15(5):497-503. PubMed ID: 7980960
[TBL] [Abstract][Full Text] [Related]
10. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat.
Kalu DN; Salerno E; Liu CC; Echon R; Ray M; Garza-Zapata M; Hollis BW
Bone Miner; 1991 Nov; 15(2):109-23. PubMed ID: 1764629
[TBL] [Abstract][Full Text] [Related]
12. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic treatment with oestrogen, an oestrogen antagonist and a potent luteinizing hormone releasing hormone agonist analogue on pituitary responsiveness to luteinizing hormone releasing hormone in the rat.
Hall JM; Whitehead SA
J Endocrinol; 1983 Sep; 98(3):313-21. PubMed ID: 6413634
[TBL] [Abstract][Full Text] [Related]
14. Effects of clomiphene and tamoxifen in vivo on the bone-resorbing effects of parathyroid hormone and of high oral doses of calcitriol (1,25(OH)2D3) in rats with intact ovarian function consuming low calcium diet.
Goulding A; Gold E; Fisher L
Bone Miner; 1990 Mar; 8(3):185-93. PubMed ID: 2322693
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
16. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
[TBL] [Abstract][Full Text] [Related]
17. The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer.
Koibuchi Y; Sugamata N; Iino Y; Yokoe T; Andoh T; Maemura M; Takei H; Horiguchi J; Matsumoto H; Morishita Y
Int J Mol Med; 1999 Aug; 4(2):145-8. PubMed ID: 10402480
[TBL] [Abstract][Full Text] [Related]
18. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Kuhl H; Jung C; Taubert HD
Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
[TBL] [Abstract][Full Text] [Related]
19. Effect of administration and subsequent cessation of buserelin on cancellous bone of female rats.
Tobias JH; Chambers TJ; Gallagher A
J Bone Miner Res; 1994 Dec; 9(12):1919-25. PubMed ID: 7872057
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
